Abstract
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology. Our study evaluated the potential role of serum vascular endothelial growth factor (VEGF) as a predictive biomarker of clinical benefit and response to treatment with ICIs.Methods: Pre-treatment peripheral blood samples were obtained from advanced melanoma patients undergoing ICI therapy as monotherapy or in combination at two tertiary care hospitals in Western Australia. Serum VEGF levels were correlated with response to therapy and survival outcomes.Results: Serum VEGF samples were collected from a total of 130 patients treated with ICI therapy (pembrolizumab 73, ipilimumab 15, and ipilimumab/nivolumab combination 42). Median serum VEGF level was significantly higher in the non-responders (82.15 pg/mL) vs. responders (60.40 pg/mL) in the ipilimumab monotherapy cohort (P < 0.0352). However, no difference was seen in VEGF levels between non-responders and responders in pembrolizumab and ipilimumab/nivolumab treated patients.Conclusions: The results of our study confirm previous observations that that high pre-treatment serum VEGF levels in advanced melanoma patients may predict poor response to ipilimumab. However, serum VEGF is not predictive of outcome in patients treated with anti-PD-1 agents alone or in combination with ipilimumab.
Highlights
Immune checkpoint inhibitors (ICIs) have improved the survival of advanced melanoma patients with a 5 year survival rate of about 50% [1, 2]
Serum samples were collected from a total of 130 patients treated with ICI therapy as follows: pembrolizumab 73, ipilimumab 15, and ipilimumab/nivolumab combination 42
Serum levels vascular endothelial growth factor (VEGF) was similar between the patient groups, with 32–450 pg/mL in the ipilimumab group, 25–330 pg/mL in anti-PDL1 treated group, and 24–490 pg/mL in the combination group
Summary
Immune checkpoint inhibitors (ICIs) have improved the survival of advanced melanoma patients with a 5 year survival rate of about 50% [1, 2]. Biomarkers predictive of response to ICI therapy in advanced melanoma are lacking. Blood based markers are relatively non-invasive with an advantage of longitudinal sample collection allowing us to potentially track an evolving antitumour immune response. One such marker is serum vascular endothelial growth factor (VEGF) [9]. The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology. Our study evaluated the potential role of serum vascular endothelial growth factor (VEGF) as a predictive biomarker of clinical benefit and response to treatment with ICIs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
